Loop diuretic adjustments in patients with chronic heart failure: Insights from HF-ACTION

Marat Fudim, Christopher M. O'Connor, Hillary Mulder, Adrian Coles, Ankeet S. Bhatt, Andrew P. Ambrosy, William E. Kraus, Ileana L. Pina, David J. Whellan, Robert J. Mentz

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Background: The relationship between diuretic use or change in diuretic use and outcomes in chronic heart failure (HF) remains poorly defined. We evaluated the association between diuretic use and changes in health status, exercise capacity, and clinical events in a large randomized trial of subjects with HF. Methods: HF-ACTION randomized 2,331 outpatients with HF and ejection fraction ≤35% to aerobic exercise training versus usual care. We grouped patients according to loop diuretic use from baseline through 6 months: continued use, never use, initiated, and discontinued. The association between diuretic use and changes in health status, exercise capacity, and clinical outcomes (all-cause mortality/hospitalization, cardiovascular mortality, and HF hospitalization) through 12 months was assessed using Cox proportional hazards models and generalized linear regression models, respectively. Results: A total of 2,004 (86%) patients had complete data on diuretic use. There was no association between diuretic status and Kansas City Cardiomyopathy Questionnaire, 6-minute walk distance, or peak VO2 in adjusted analyses (all P >.05). A dose increase was associated with decrease in 6-minute walk distance (−4.25 m, SE 1.12 m, P <.001) and change in Kansas City Cardiomyopathy Questionnaire overall score (−0.56 m, SE 0.24 m, P =.02). There were no between-group differences for all-cause death or hospitalization comparing continuous use versus never use (adjusted HR 0.91; 95% CI 0.72-1.15; P =.432). Conclusions: The initiation or discontinuation of diuretics over a 6-month time frame was not associated with a difference in mortality, hospitalizations, exercise, or health status outcomes, but a dose increase in HF patients was associated with worse exercise and health status outcomes.

Original languageEnglish (US)
JournalAmerican Heart Journal
DOIs
StateAccepted/In press - Jan 1 2018
Externally publishedYes

Fingerprint

Sodium Potassium Chloride Symporter Inhibitors
Diuretics
Heart Failure
Exercise
Health Status
Hospitalization
Cardiomyopathies
Mortality
Linear Models
Proportional Hazards Models
Cause of Death
Outpatients

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Fudim, M., O'Connor, C. M., Mulder, H., Coles, A., Bhatt, A. S., Ambrosy, A. P., ... Mentz, R. J. (Accepted/In press). Loop diuretic adjustments in patients with chronic heart failure: Insights from HF-ACTION. American Heart Journal. https://doi.org/10.1016/j.ahj.2018.06.017

Loop diuretic adjustments in patients with chronic heart failure : Insights from HF-ACTION. / Fudim, Marat; O'Connor, Christopher M.; Mulder, Hillary; Coles, Adrian; Bhatt, Ankeet S.; Ambrosy, Andrew P.; Kraus, William E.; Pina, Ileana L.; Whellan, David J.; Mentz, Robert J.

In: American Heart Journal, 01.01.2018.

Research output: Contribution to journalArticle

Fudim, M, O'Connor, CM, Mulder, H, Coles, A, Bhatt, AS, Ambrosy, AP, Kraus, WE, Pina, IL, Whellan, DJ & Mentz, RJ 2018, 'Loop diuretic adjustments in patients with chronic heart failure: Insights from HF-ACTION', American Heart Journal. https://doi.org/10.1016/j.ahj.2018.06.017
Fudim, Marat ; O'Connor, Christopher M. ; Mulder, Hillary ; Coles, Adrian ; Bhatt, Ankeet S. ; Ambrosy, Andrew P. ; Kraus, William E. ; Pina, Ileana L. ; Whellan, David J. ; Mentz, Robert J. / Loop diuretic adjustments in patients with chronic heart failure : Insights from HF-ACTION. In: American Heart Journal. 2018.
@article{679aab78d6e947c4b64b6d6bceb6d70b,
title = "Loop diuretic adjustments in patients with chronic heart failure: Insights from HF-ACTION",
abstract = "Background: The relationship between diuretic use or change in diuretic use and outcomes in chronic heart failure (HF) remains poorly defined. We evaluated the association between diuretic use and changes in health status, exercise capacity, and clinical events in a large randomized trial of subjects with HF. Methods: HF-ACTION randomized 2,331 outpatients with HF and ejection fraction ≤35{\%} to aerobic exercise training versus usual care. We grouped patients according to loop diuretic use from baseline through 6 months: continued use, never use, initiated, and discontinued. The association between diuretic use and changes in health status, exercise capacity, and clinical outcomes (all-cause mortality/hospitalization, cardiovascular mortality, and HF hospitalization) through 12 months was assessed using Cox proportional hazards models and generalized linear regression models, respectively. Results: A total of 2,004 (86{\%}) patients had complete data on diuretic use. There was no association between diuretic status and Kansas City Cardiomyopathy Questionnaire, 6-minute walk distance, or peak VO2 in adjusted analyses (all P >.05). A dose increase was associated with decrease in 6-minute walk distance (−4.25 m, SE 1.12 m, P <.001) and change in Kansas City Cardiomyopathy Questionnaire overall score (−0.56 m, SE 0.24 m, P =.02). There were no between-group differences for all-cause death or hospitalization comparing continuous use versus never use (adjusted HR 0.91; 95{\%} CI 0.72-1.15; P =.432). Conclusions: The initiation or discontinuation of diuretics over a 6-month time frame was not associated with a difference in mortality, hospitalizations, exercise, or health status outcomes, but a dose increase in HF patients was associated with worse exercise and health status outcomes.",
author = "Marat Fudim and O'Connor, {Christopher M.} and Hillary Mulder and Adrian Coles and Bhatt, {Ankeet S.} and Ambrosy, {Andrew P.} and Kraus, {William E.} and Pina, {Ileana L.} and Whellan, {David J.} and Mentz, {Robert J.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1016/j.ahj.2018.06.017",
language = "English (US)",
journal = "American Heart Journal",
issn = "0002-8703",
publisher = "Mosby Inc.",

}

TY - JOUR

T1 - Loop diuretic adjustments in patients with chronic heart failure

T2 - Insights from HF-ACTION

AU - Fudim, Marat

AU - O'Connor, Christopher M.

AU - Mulder, Hillary

AU - Coles, Adrian

AU - Bhatt, Ankeet S.

AU - Ambrosy, Andrew P.

AU - Kraus, William E.

AU - Pina, Ileana L.

AU - Whellan, David J.

AU - Mentz, Robert J.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Background: The relationship between diuretic use or change in diuretic use and outcomes in chronic heart failure (HF) remains poorly defined. We evaluated the association between diuretic use and changes in health status, exercise capacity, and clinical events in a large randomized trial of subjects with HF. Methods: HF-ACTION randomized 2,331 outpatients with HF and ejection fraction ≤35% to aerobic exercise training versus usual care. We grouped patients according to loop diuretic use from baseline through 6 months: continued use, never use, initiated, and discontinued. The association between diuretic use and changes in health status, exercise capacity, and clinical outcomes (all-cause mortality/hospitalization, cardiovascular mortality, and HF hospitalization) through 12 months was assessed using Cox proportional hazards models and generalized linear regression models, respectively. Results: A total of 2,004 (86%) patients had complete data on diuretic use. There was no association between diuretic status and Kansas City Cardiomyopathy Questionnaire, 6-minute walk distance, or peak VO2 in adjusted analyses (all P >.05). A dose increase was associated with decrease in 6-minute walk distance (−4.25 m, SE 1.12 m, P <.001) and change in Kansas City Cardiomyopathy Questionnaire overall score (−0.56 m, SE 0.24 m, P =.02). There were no between-group differences for all-cause death or hospitalization comparing continuous use versus never use (adjusted HR 0.91; 95% CI 0.72-1.15; P =.432). Conclusions: The initiation or discontinuation of diuretics over a 6-month time frame was not associated with a difference in mortality, hospitalizations, exercise, or health status outcomes, but a dose increase in HF patients was associated with worse exercise and health status outcomes.

AB - Background: The relationship between diuretic use or change in diuretic use and outcomes in chronic heart failure (HF) remains poorly defined. We evaluated the association between diuretic use and changes in health status, exercise capacity, and clinical events in a large randomized trial of subjects with HF. Methods: HF-ACTION randomized 2,331 outpatients with HF and ejection fraction ≤35% to aerobic exercise training versus usual care. We grouped patients according to loop diuretic use from baseline through 6 months: continued use, never use, initiated, and discontinued. The association between diuretic use and changes in health status, exercise capacity, and clinical outcomes (all-cause mortality/hospitalization, cardiovascular mortality, and HF hospitalization) through 12 months was assessed using Cox proportional hazards models and generalized linear regression models, respectively. Results: A total of 2,004 (86%) patients had complete data on diuretic use. There was no association between diuretic status and Kansas City Cardiomyopathy Questionnaire, 6-minute walk distance, or peak VO2 in adjusted analyses (all P >.05). A dose increase was associated with decrease in 6-minute walk distance (−4.25 m, SE 1.12 m, P <.001) and change in Kansas City Cardiomyopathy Questionnaire overall score (−0.56 m, SE 0.24 m, P =.02). There were no between-group differences for all-cause death or hospitalization comparing continuous use versus never use (adjusted HR 0.91; 95% CI 0.72-1.15; P =.432). Conclusions: The initiation or discontinuation of diuretics over a 6-month time frame was not associated with a difference in mortality, hospitalizations, exercise, or health status outcomes, but a dose increase in HF patients was associated with worse exercise and health status outcomes.

UR - http://www.scopus.com/inward/record.url?scp=85052315350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052315350&partnerID=8YFLogxK

U2 - 10.1016/j.ahj.2018.06.017

DO - 10.1016/j.ahj.2018.06.017

M3 - Article

C2 - 30158057

AN - SCOPUS:85052315350

JO - American Heart Journal

JF - American Heart Journal

SN - 0002-8703

ER -